Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds
作者:Subhas S. Karki、Sreekanth Thota、Satyanarayana Y. Darj、Jan Balzarini、Erik De Clercq
DOI:10.1016/j.bmc.2007.08.014
日期:2007.11
The synthesis and characterization of ruthenium compounds (Ru1-Ru12) of the type [Ru(S)(2)(K)], (where S = 1,10-phenanthrohne/2,2'-bipyridine and K = itsz, MeO-btsz, 4-Cl-btsz, 2-Cl-btsz, 2-F-btsz, He and itsz = isatin-3-thiosemicarbazone, MeO-btsz = 1-(4'-methoxy-benzyl)-thiosemicarbazoiie, hFc = 2-[3-chloro-4-fluoro-phenylimino]methyl}phenol, 4-Cl-btsz = 1-(4'chlorobenzyl)-thiosemicarbazone, 2-Cl-btsz =1-(2'-chloro benzyl)-thiosemicarbazone, 2-F-btsz = 1-(2'-fluorobenzyl)-thiosemicarbazone) are described. These ligands form bidentate octahedral ruthenium compounds. The title compounds were subjected to in vivo anticancer activity against a transplantable murine tumor cell line Ehrlich's Ascites Carcinoma (EAC) and in vitro cytotoxic activity against human cancer cell line Molt 4/C8, CEM and murine tumor cell line L1210. Ruthenium compounds (Ru1-Rul2) showed promising biological activity especially in decreasing tumor volume and viable ascites cell counts. Treatment with these compounds prolonged the life span of mice bearing EAC tumor by 10-43%. In vitro evaluation of these ruthenium compounds revealed cytotoxic activity from 0.24 to 27 mu M against Molt 4/C8, 0.27 to 48 mu M against CEM, and 0.94 to 248 mu M against L1210. Their ligands alone failed to show cytotoxic activity at the concentrations tested (68-405 mu M). (C) 2007 Elsevier Ltd. All rights reserved.